Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | THPO | P40225 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.39 |
| ▸ | MME | P08473 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | CPA1 | P15085 | 1/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alanine SCHEMBL20898432 | 1.00 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2KDM4EMAPTTHRB | |
| Alanine SCHEMBL7699776 | 1.00 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2KDM4EMAPTTHRB | |
| D-Alanine SCHEMBL6862079 | 1.00 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL330009 | 0.90 | — | — | |
| SCHEMBL330011 | 0.90 | — | — | |
| SCHEMBL330308 | 0.90 | — | — | |
| SCHEMBL29078950 | 0.87 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL29078952 | 0.87 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL11433892 | 0.87 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2KDM4EMAPTTHRB | |
| Hydrochloric Acid SCHEMBL28235390 | 0.87 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2KDM4EMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158101-A1 | GLYCOPEPTIDE COMPOSITIONS | HIKMA PHARMACEUTICALS USA INC. | 2023-05-25 | — | — | US | disclosed |
| US-11628200-B2 | Glycopeptide compositions | XELLIA PHARMACEUTICALS APS (DK) | 2023-04-18 | — | — | US | disclosed |
| EP-4147710-A1 | GLYCOPEPTIDE COMPOSITIONS IN SOLUTION | Xellia Pharmaceuticals ApS (DK) | 2023-03-15 | — | — | EP | disclosed |
| US-11517609-B2 | Glycopeptide compositions | XELLIA PHARMACEUTICALS APS (DK) | 2022-12-06 | — | — | US | disclosed |
| US-20210220433-A1 | Glycopeptide Compositions | XELLIA PHARMACEUTICALS APS (DK) | 2021-07-22 | — | — | US | disclosed |
| EP-3834837-A1 | GLYCOPEPTIDE COMPOSITIONS | Xellia Pharmaceuticals ApS (DK) | 2021-06-16 | — | — | EP | disclosed |
| US-11000567-B2 | Glycopeptide compositions | XELLIA PHARMACEUTICALS APS | 2021-05-11 | — | — | US | disclosed |
| EP-3542812-B1 | GLYCOPEPTIDE COMPOSITIONS | XELLIA PHARMACEUTICALS APS (DK) | 2021-01-13 | — | — | EP | disclosed |
| US-10849956-B2 | Glycopeptide compositions | XELLIA PHARMACEUTICALS APS | 2020-12-01 | — | — | US | disclosed |
| US-20200069768-A1 | GLYCOPEPTIDE COMPOSITIONS | HIKMA PHARMACEUTICALS USA INC. | 2020-03-05 | — | — | US | disclosed |
| EP-3542812-A1 | GLYCOPEPTIDE COMPOSITIONS | Xellia Pharmaceuticals ApS (DK) | 2019-09-25 | — | — | EP | disclosed |
| US-20190160142-A1 | GLYCOPEPTIDE COMPOSITIONS | HIKMA PHARMACEUTICALS USA INC. | 2019-05-30 | — | — | US | disclosed |
| US-10188697-B2 | Glycopeptide compositions | XELLIA PHARMACEUTICALS APS (DK) | 2019-01-29 | — | — | US | disclosed |
| US-10039804-B2 | Glycopeptide compositions | XELLIA PHARMACEUTICALS APS (DK) | 2018-08-07 | — | — | US | disclosed |
| US-20180133286-A1 | GLYCOPEPTIDE COMPOSITIONS | HIKMA PHARMACEUTICALS USA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20170348385-A1 | GLYCOPEPTIDE COMPOSITIONS | HIKMA PHARMACEUTICALS USA INC. | 2017-12-07 | — | — | US | disclosed |
| EP-3215173-A1 | GLYCOPEPTIDE COMPOSITIONS | Xellia Pharmaceuticals ApS (DK) | 2017-09-13 | — | — | EP | disclosed |
| WO-2016071495-A1 | GLYCOPEPTIDE COMPOSITIONS | XELLIA PHARMACEUTICALS APS (DK) | 2016-05-12 | — | — | WO | disclosed |
| US-6800608-B2 | PREPARATION OF STABILIZED GLYCOPEPTIDE ANTIBIOTIC CONJUGATE; FORM GLYCOPEPTIDE ANTIBIOTIC, MIX WITH STABILIZING AGENT THAT PREVENTS DIMERIZATION, HEAT, STORE IN DILUENT BUFFER | BECKMAN COULTER, INC. | 2004-10-05 | — | — | US | disclosed |
| US-20030077670-A1 | Homogeneous assay of vancomycin using a stable particle-vancomycin conjugate, a novel rate enhancer, and a novel dose response modulator | BECKMAN COULTER, INC. | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11517609-B2 | Glycopeptide compositions | ASNS, B3GNT2, OGT | ALDH1A1 2956/4885SMN1; SMN2 2214/4885KDM4E 4745/4885 |
| US-20200069768-A1 | GLYCOPEPTIDE COMPOSITIONS | ASNS, B3GNT2, OGT | ALDH1A1 2956/4885SMN1; SMN2 2214/4885KDM4E 4745/4885 |
| US-20190160142-A1 | GLYCOPEPTIDE COMPOSITIONS | ASNS, B3GNT2, OGT | ALDH1A1 2956/4885SMN1; SMN2 2214/4885KDM4E 4745/4885 |
| US-11000567-B2 | Glycopeptide compositions | ASNS, B3GNT2, OGT | ALDH1A1 2956/4885SMN1; SMN2 2214/4885KDM4E 4745/4885 |
| US-10039804-B2 | Glycopeptide compositions | ASNS, B3GNT2, OGT | ALDH1A1 2956/4885SMN1; SMN2 2214/4885KDM4E 4745/4885 |
| US-20230158101-A1 | GLYCOPEPTIDE COMPOSITIONS | ASNS, OGT, B3GNT2 | ALDH1A1 3475/4885SMN1; SMN2 2847/4885KDM4E 4690/4885 |
| US-20210220433-A1 | Glycopeptide Compositions | ASNS, B3GNT2, OGT | ALDH1A1 2956/4885SMN1; SMN2 2214/4885KDM4E 4745/4885 |
| US-11628200-B2 | Glycopeptide compositions | ASNS, B3GNT2, OGT | ALDH1A1 2956/4885SMN1; SMN2 2214/4885KDM4E 4745/4885 |
| US-20180133286-A1 | GLYCOPEPTIDE COMPOSITIONS | ASNS, B3GNT2, OGT | ALDH1A1 2956/4885SMN1; SMN2 2214/4885KDM4E 4745/4885 |
| US-10849956-B2 | Glycopeptide compositions | ASNS, B3GNT2, OGT | ALDH1A1 2956/4885SMN1; SMN2 2214/4885KDM4E 4745/4885 |
| US-20170348385-A1 | GLYCOPEPTIDE COMPOSITIONS | ASNS, B3GNT2, OGT | ALDH1A1 2956/4885SMN1; SMN2 2214/4885KDM4E 4745/4885 |
| US-10188697-B2 | Glycopeptide compositions | ASNS, B3GNT2, OGT | ALDH1A1 2956/4885SMN1; SMN2 2214/4885KDM4E 4745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.